Go offline with the Player FM app!
Leading A tRNA Startup With Alltrna's Michelle Werner
Manage episode 483686569 series 2739469
We love to hear from our listeners. Send us a message.
On this week's episode, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at Advancing RNA. Werner explains why a single engineered tRNA therapy has the potential to treat "hundreds, if not thousands," of rare genetic diseases, and how her own child's rare disease diagnosis shaped her career and approach to drug development. Werner also discusses Alltrna's use of AI and machine learning for drug optimization, the company's planned use of basket trials, and more.
This episode is brought to you by Avantor. For more information, visit avantorsciences.com
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Chapters
1. Introduction to Michelle Werner and Alterna (00:00:00)
2. Personal Journey from Oncology to Rare Disease (00:02:11)
3. Transitioning from Big Pharma to Biotech CEO (00:08:52)
4. Understanding tRNA's Transformative Potential (00:13:33)
5. The Basket Trial Approach for Multiple Diseases (00:22:37)
6. Reclassifying Patients with Stop Codon Disease (00:27:58)
7. AI and Machine Learning in tRNA Design (00:35:29)
8. Manufacturing and Regulatory Considerations (00:42:32)
9. Leadership Support and Future Challenges (00:52:19)
10. Closing Remarks (00:57:26)
255 episodes
Manage episode 483686569 series 2739469
We love to hear from our listeners. Send us a message.
On this week's episode, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at Advancing RNA. Werner explains why a single engineered tRNA therapy has the potential to treat "hundreds, if not thousands," of rare genetic diseases, and how her own child's rare disease diagnosis shaped her career and approach to drug development. Werner also discusses Alltrna's use of AI and machine learning for drug optimization, the company's planned use of basket trials, and more.
This episode is brought to you by Avantor. For more information, visit avantorsciences.com
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Chapters
1. Introduction to Michelle Werner and Alterna (00:00:00)
2. Personal Journey from Oncology to Rare Disease (00:02:11)
3. Transitioning from Big Pharma to Biotech CEO (00:08:52)
4. Understanding tRNA's Transformative Potential (00:13:33)
5. The Basket Trial Approach for Multiple Diseases (00:22:37)
6. Reclassifying Patients with Stop Codon Disease (00:27:58)
7. AI and Machine Learning in tRNA Design (00:35:29)
8. Manufacturing and Regulatory Considerations (00:42:32)
9. Leadership Support and Future Challenges (00:52:19)
10. Closing Remarks (00:57:26)
255 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.